279 related articles for article (PubMed ID: 30419062)
1. Association of specific gene mutations derived from machine learning with survival in lung adenocarcinoma.
Cho HJ; Lee S; Ji YG; Lee DH
PLoS One; 2018; 13(11):e0207204. PubMed ID: 30419062
[TBL] [Abstract][Full Text] [Related]
2. A large cohort study identifying a novel prognosis prediction model for lung adenocarcinoma through machine learning strategies.
Li Y; Ge D; Gu J; Xu F; Zhu Q; Lu C
BMC Cancer; 2019 Sep; 19(1):886. PubMed ID: 31488089
[TBL] [Abstract][Full Text] [Related]
3. Elevated PHD2 expression might serve as a valuable biomarker of poor prognosis in lung adenocarcinoma, but no lung squamous cell carcinoma.
Xu XL; Gong Y; Zhao DP
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8731-8739. PubMed ID: 30575913
[TBL] [Abstract][Full Text] [Related]
4. The genomic alterations of lung adenocarcinoma and lung squamous cell carcinoma can explain the differences of their overall survival rates.
Meng F; Zhang L; Ren Y; Ma Q
J Cell Physiol; 2019 Jul; 234(7):10918-10925. PubMed ID: 30549039
[TBL] [Abstract][Full Text] [Related]
5. Intratumoral immunoglobulin isotypes predict survival in lung adenocarcinoma subtypes.
Isaeva OI; Sharonov GV; Serebrovskaya EO; Turchaninova MA; Zaretsky AR; Shugay M; Chudakov DM
J Immunother Cancer; 2019 Oct; 7(1):279. PubMed ID: 31665076
[TBL] [Abstract][Full Text] [Related]
6. A ten-gene signature-based risk assessment model predicts the prognosis of lung adenocarcinoma.
Jiang H; Xu S; Chen C
BMC Cancer; 2020 Aug; 20(1):782. PubMed ID: 32819300
[TBL] [Abstract][Full Text] [Related]
7. Identifying the miRNA signature associated with survival time in patients with lung adenocarcinoma using miRNA expression profiles.
Yerukala Sathipati S; Ho SY
Sci Rep; 2017 Aug; 7(1):7507. PubMed ID: 28790336
[TBL] [Abstract][Full Text] [Related]
8. Nonnegative matrix factorization-based bioinformatics analysis reveals that TPX2 and SELENBP1 are two predictors of the inner sub-consensuses of lung adenocarcinoma.
Wang H; Wang X; Xu L; Cao H; Zhang J
Cancer Med; 2021 Dec; 10(24):9058-9077. PubMed ID: 34734491
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of clinical value and potential mechanism of MTFR2 in lung adenocarcinoma via bioinformatics.
Chen C; Tang Y; Qu WD; Han X; Zuo JB; Cai QY; Xu G; Song YX; Ke XX
BMC Cancer; 2021 May; 21(1):619. PubMed ID: 34039308
[TBL] [Abstract][Full Text] [Related]
10. Identification of nine microRNAs as potential biomarkers for lung adenocarcinoma.
Ren ZP; Hou XB; Tian XD; Guo JT; Zhang LB; Xue ZQ; Deng JQ; Zhang SW; Pan JY; Chu XY
FEBS Open Bio; 2019 Feb; 9(2):315-327. PubMed ID: 30761256
[TBL] [Abstract][Full Text] [Related]
11. USP4 expression independently predicts favorable survival in lung adenocarcinoma.
Zhong M; Jiang Q; Jin R
IUBMB Life; 2018 Jul; 70(7):670-677. PubMed ID: 29667299
[TBL] [Abstract][Full Text] [Related]
12. Identification of diagnostic DNA methylation biomarkers specific for early-stage lung adenocarcinoma.
Cai Q; Zhang P; He B; Zhao Z; Zhang Y; Peng X; Xie H; Wang X
Cancer Genet; 2020 Aug; 246-247():1-11. PubMed ID: 32805686
[TBL] [Abstract][Full Text] [Related]
13. Systematical identifications of prognostic meaningful lung adenocarcinoma subtypes and the underlying mutational and expressional characters.
Lv Z; Lei T
BMC Cancer; 2020 Jan; 20(1):56. PubMed ID: 31987030
[TBL] [Abstract][Full Text] [Related]
14. Genome-wide isoform-level analysis reveals tumor-specific isoforms for lung adenocarcinoma diagnosis and prognosis.
Zhuhong H; Zhenyu B; Xiangyuan C; Tingzhen X; Libin S
Cancer Genet; 2019 Jan; 230():58-65. PubMed ID: 30470588
[TBL] [Abstract][Full Text] [Related]
15. Integrating genetic mutations and expression profiles for survival prediction of lung adenocarcinoma.
Song Y; Chen D; Zhang X; Luo Y; Li S
Thorac Cancer; 2019 May; 10(5):1220-1228. PubMed ID: 30993904
[TBL] [Abstract][Full Text] [Related]
16. Identification of an immune signature predicting prognosis risk of patients in lung adenocarcinoma.
Song Q; Shang J; Yang Z; Zhang L; Zhang C; Chen J; Wu X
J Transl Med; 2019 Mar; 17(1):70. PubMed ID: 30832680
[TBL] [Abstract][Full Text] [Related]
17. Immune-related eight-lncRNA signature for improving prognosis prediction of lung adenocarcinoma.
Chen Y; Zhang X; Li J; Zhou M
J Clin Lab Anal; 2021 Nov; 35(11):e24018. PubMed ID: 34550610
[TBL] [Abstract][Full Text] [Related]
18. High expression of RRM2 as an independent predictive factor of poor prognosis in patients with lung adenocarcinoma.
Jin CY; Du L; Nuerlan AH; Wang XL; Yang YW; Guo R
Aging (Albany NY); 2020 Dec; 13(3):3518-3535. PubMed ID: 33411689
[TBL] [Abstract][Full Text] [Related]
19. Isoform specific gene expression analysis of KRAS in the prognosis of lung adenocarcinoma patients.
Yang IS; Kim S
BMC Bioinformatics; 2018 Feb; 19(Suppl 1):40. PubMed ID: 29504894
[TBL] [Abstract][Full Text] [Related]
20. Increased expression of TTC21A in lung adenocarcinoma infers favorable prognosis and high immune infiltrating level.
Wang W; Ren S; Wang Z; Zhang C; Huang J
Int Immunopharmacol; 2020 Jan; 78():106077. PubMed ID: 31812070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
